cancel, without prejudice to the subject matter involved, claim 39 and insert in its stead the following claim:

--4/7. A compound according to claim 2/9, said compound being 7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3-1,2,3-triazol-5-yl thiomethyl-3-cephem-4-carboxylic acid.--

Cancel, without prejudice to the subject matter involved,

claim 40 and insert in its stead the following claim:

--45. A compound according to claim 25, said emopbund being

7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3
1,2,3-thiadiazol-5-yl thiomethyl-3-cephem-4-carboxylic acid or

7beta-[2-(2-aminothiazol-4-yl)-4-carboxy-2-butenoylamino]-3
1,3,4-thiadiazol-5-yl thiomethyl-3-cephem-4-carboxylic acid.--

Claim 41, line 3, correct the spelling of "carboxylic".

Claim 43, line 3, change "fluoroethylthio" to read --2-fluoroethylthio--.

Claim 44, line 3, change "trifluoroethylthio" to read --2,2,2-trifluoroethylthio--.

REMARKS

Further and favorable reconsideration is respectfully requested.

The application has been reviewed for errors and certain minor clerical changes are effected in the specification. It is believed that these are purely editorial in nature and would thus not appear to require extensive discussion.

The claims of the application are amended in a manner to overcome the objections raised by the Examiner in the recent Official Action. Claim 29 is amended to delete the term "a lower aralkyl group" and to replace it by a more specific definition of the groups intended based upon the instant specification at page 5. This is accomplished in both instances where the term was formerly used in connection with the definitions of the group R³ and R⁶. Further, the term "a lower alkylene group" within the definition of the group R³ has been corrected to read "a lower alkyl group". It is believed that these changes will overcome the Examiner's objections to claim 29 as stated in items 1 and 2, page 2 of the Official Action.

Claim 39 has been cancelled and new claim 47 inserted in its stead. In the new claim, the spelling of the term "aminothiazol" has been corrected. Also, in the new claim, the triazol moiety is more specifically defined. See Example 17 of the application, page 98.

Claim 40 has been cancelled and new claim 48 inserted in its stead. In the new claim, two compounds are specified, the difference residing in the thiadiazol moiety. Support is apparent from Examples Nos. 18 and 19 on pages 98 and 99 of the application.

In claim 41, the spelling of the term carboxylic has been corrected. In claim 43, the specific nature of the fluoroethyl group is specified. See Example 26, page 100 of the specification.

In claim 44, the specific nature of the trifluoroethylthio group is specified. See Example 27, page 100 of the specification.

Applicants respectfully submit that these amendments to the claims will clearly avoid each of the objections raised by the Examiner at page 2 of the Official Action and will thereby place this application in immediate condition for allowance.

Applicants respectfully submit that each of the grounds of rejection set forth against the application has now been overcome and that the application is in condition for allowance; such allowance is solicited.

Respectfully submitted,
YOHSIO HAMASHIMA

D.r.

JOHN T. MILLER

Registration No. 21120

JTM/vca Washington, D. C. Telephone 393-5150 June 2, 1986